
Srivenn Formulations Private Limited
Pharmaceutical company specializing in buying, selling, and manufacturing medicines and healthcare products.
Pharmaceutical company specializing in buying, selling, and manufacturing medicines and healthcare products.
Hyderabad, Telangana, India
+91-XXXXXXXXXX
U51101TG2012PTC083273
083273
Private Limited Indian Non-Government Company
25 Sep 2012
30 Sep 2023
31 Mar 2023
Unlisted
Roc Hyderabad
Name | Designation | Appointment Date | Status |
---|---|---|---|
Sapna Agarwal ![]() | Director | 25-Sep-2012 | Current |
Manoj Agarwal ![]() | Director | 25-Sep-2012 | Current |
Srivenn Formulations Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue | |||||||
Revenue from Operations | |||||||
Total Assets | |||||||
Profit or Loss | |||||||
Net Worth | |||||||
EBITDA |
In 2022, Srivenn Formulations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Sapna Agarwal and Manoj Agarwal are mutual person
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with Srivenn Formulations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Srivenn Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Srivenn Formulations's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Srivenn Formulations Private Limited last Annual general meeting of members was held on 30 Sep 2023 as per latest MCA records.
Srivenn Formulations Private Limited has filed its annual Financial statements for the year ended 31 Mar 2023 with Roc Hyderabad.
Sapna Agarwal was appointed as a Director was appointed as a Director on 25 Sep 2012 & has been associated with this company since 12 years 6 months .
Manoj Kumar Agarwal was appointed as a Director was appointed as a Director on 25 Sep 2012 & has been associated with this company since 12 years 6 months .
Srivenn Formulations Private Limited was registered on 25 Sep 2012 with Roc Hyderabad & aged 12 years 6 months as per MCA records.
Srivenn Formulations Private Limited was incorporated on 25 Sep 2012.
The authorized share capital of Srivenn Formulations Private Limited is ₹ 0.10 M and paid-up capital is ₹ 0.10 M.
Currently 2 directors are associated with Srivenn Formulations Private Limited.
As per Ministry of Corporate Affairs (Mca), the registered address of Srivenn Formulations Private Limited is 21-1-732/C/5 2Nd Floor Gopal Market, Rikab Gunj India, Hyderabad, Telangana, 500002.
The corporate identification number (CIN) of Srivenn Formulations Private Limited is U51101TG2012PTC083273 and the company number is 083273 as per Ministry of Corporate Affairs (MCA).
The most recent Balance Sheet for Srivenn Formulations Private Limited was filed with the ROC on 31 Mar 2023.